Towards Healthcare Research & Consulting

Erectile Dysfunction Treatment Key Players and their Developments

Date : 06 July 2026

Who are the Erectile Dysfunction Treatment Market Top Vendors and What are Their Offerings?

Erectile Dysfunction Treatment Market Companies are Pfizer Inc., Vivus LLC, Eli Lilly And Company, Petros Pharmaceuticals, Inc., Bayer AG, Viatris Inc., Futura Medical plc

Erectile Dysfunction Treatment Market Value Chain Analysis

R&D

  • The R&D of the erectile dysfunction treatment focuses on the development of transdermal topical gels, fast-acting oral PDE5 inhibitors, and micro-plaque sonic devices.
  • Key players: Futura Medical plc, Vivus LLC, and Strategic Science & Technologies.

Clinical Trials and Regulatory Approvals

  • The minimal clinically important difference (MCID), safety, and systemic adverse events are evaluated in the clinical trials and regulatory approvals of the erectile dysfunction treatment.
  • Key players: Futura Medical plc, Vivus LLC.

Patient Support and Services

  • The digital health platforms, retail programs offering online medical consultations, automated educational resources, and home deliveries are provided in the patient support and services of the erectile dysfunction treatment.
  • Key players: Ro, Him & Hers Health, Inc., Haleon plc.

Market Ecosystem Analysis

Ecosystem Category Major Participants Role in the Market
Technology Providers Boston Scientific, Coloplast, Rigicon, Zephyr Surgical Implants Develop penile prostheses, implants, and minimally invasive treatment technologies.
Product Manufacturers Viatris, Bayer AG, Eli Lilly and Company, Pfizer Inc., Ferring Pharmaceuticals Manufacture PDE5 inhibitors, injectable therapies, hormonal treatments, and other ED therapeutics.
Service Providers Owens & Minor, McKesson Corporation, Cardinal Health Distribution, specialty pharmacy support, hospital supply, and commercialization services.
Platform Providers Hims & Hers Health, Ro (Roman), GoodRx Digital consultation, e-prescriptions, telehealth, medication fulfillment, and patient engagement.
CROs/CDMOs IQVIA, ICON plc, Syneos Health, Parexel Clinical development, regulatory support, and commercialization services for ED therapeutics.
Software Vendors Epic Systems, Oracle Health, Athenahealth Electronic health records and patient management systems supporting urology practices.
Research Institutions Mayo Clinic, Cleveland Clinic, Johns Hopkins University, Karolinska Institute Clinical research in sexual medicine, regenerative therapies, stem cell therapy, and vascular dysfunction.
End-User Industries Hospitals, Specialty Urology Clinics, Academic Medical Centers, Ambulatory Surgery Centers Primary treatment and surgical intervention settings.

Recent Developments in the Erectile Dysfunction Treatment Market

  • In June 2026, a nationwide telehealth platform designed to help men access personalized erectile dysfunction treatment was launched by Vigo MD. This streamlined digital healthcare solution will offer a convenient, clinician-guided online experience by combining licensed medical evaluations, ongoing provider oversight, discreet medication delivery, and prescription treatment options.
  • In February 2026, Vybrique, which is the first oral film formulation of sildenafil for the treatment of erectile dysfunction, was approved by the FDA. The product will be available for men aged 18 years and older, where the tablet dissolves on the tongue without water and is prescribed to be administered between 30 minutes and four hours before sexual activity, with or without food.

Competitive Landscape

Tier 1
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to Keyword
Pfizer Inc. New York, New York United States Pioneer of the modern ED pharmaceutical market; creator of Viagra with continued commercial presence Viagra (sildenafil), men's health portfolio
Eli Lilly and Company Indianapolis, Indiana United States Major global ED pharmaceutical manufacturer with strong international distribution Cialis (tadalafil)
Viatris Inc. Canonsburg, Pennsylvania United States Major supplier of branded and generic sildenafil globally through Mylan legacy operations Sildenafil, generic PDE5 inhibitors
Bayer AG Leverkusen, North Rhine-Westphalia Germany Global commercialization partner for Levitra and men's health products Levitra (vardenafil)
Boston Scientific Corporation Marlborough, Massachusetts United States Global leader in penile prostheses and advanced surgical ED treatment AMS 700 Inflatable Penile Prosthesis, Tactra Malleable Prosthesis
Tier 2
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to Keyword
Coloplast A/S Humlebæk Denmark Global leader in urological implants and penile prostheses Titan Inflatable Penile Prosthesis
Ferring Pharmaceuticals Saint-Prex Switzerland Strong presence in reproductive and men's health therapies Hormonal therapies, men's health portfolio
Endo International plc Malvern, Pennsylvania United States Commercializes injectable therapies for ED Caverject (alprostadil injection)
Recordati S.p.A. Milan Italy European commercialization of ED pharmaceuticals Fortacin and men's health portfolio
Dong-A ST Co., Ltd. Seoul South Korea Developer and marketer of ED drugs across Asian markets Zydena (udenafil)
Tier 3
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to Keyword
Rigicon Inc. Ronkonkoma, New York United States Specialized manufacturer of penile implants Infla10®, Rigi10® Penile Prosthesis
Zephyr Surgical Implants Geneva Switzerland Innovative penile prosthesis developer expanding globally ZSI 475 Penile Implant
Petros Pharmaceuticals, Inc. New York, New York United States Commercializes prescription ED medications Stendra (avanafil) commercialization
Vivus LLC Campbell, California United States Developer of avanafil before licensing; maintains men's health interests Avanafil-related assets and licensing
Hims & Hers Health, Inc. San Francisco, California United States Digital men's health platform driving ED treatment accessibility Online ED consultation, sildenafil, tadalafil distribution

Erectile Dysfunction Treatment Market Trends 2026

The global erectile dysfunction treatment market size is calculated at USD 4.98 billion in 2025, driven by growth in the geriatric population and a rise in chronic disease burden. The market continues to grow in 2026 at USD 5.38 billion due to the rising use of AI-enabled healthcare, accelerated drug development, and a rise in the focus on men's healthcare. It is expected to reach USD 10.87 billion by 2035, achieving a CAGR of 8.12% between 2026 and 2035. due to growing interest in regenerative medicines, rising minimally invasive solutions, and technological advancements. North America accounted for 38% of the market in 2025 due to its high ED diagnostic rates, growth in health awareness, and rise in healthcare spending.

Erectile Dysfunction Treatment Market Size is USD 5.38 Billion in 2026.